June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Fluid Fluctuations in Early Responders Versus Limited Early Responders to Anti-VEGF Treatment for Macular Edema Secondary To Retinal Vein Occlusion
Author Affiliations & Notes
  • Roshni Sarasi Kailar
    Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
  • Blanche Kuo
    Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
    Center for Ophthalmic Bioinformatics, Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Scott W Perkins
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, United States
  • Rishi P Singh
    Center for Ophthalmic Bioinformatics, Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   Roshni Kailar None; Blanche Kuo None; Scott Perkins None; Rishi Singh OcuSciences, Code E (Employment), Apellis, Graybug, Code F (Financial Support), Genentech/Roche, Alcon/Novartis, Gyroscope & Asceplix, Zeiss, Bausch and Lomb, Regeneron , Code I (Personal Financial Interest)
  • Footnotes
    Support  This study was supported in part by the NIH-NEI P30 Core Grant (IP30EY025585), Unrestricted Grants from The Research to Prevent Blindness, Inc., and Cleveland Eye Bank Foundation awarded to the Cole Eye Institute.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1726 – F0186. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Roshni Sarasi Kailar, Blanche Kuo, Scott W Perkins, Rishi P Singh; Fluid Fluctuations in Early Responders Versus Limited Early Responders to Anti-VEGF Treatment for Macular Edema Secondary To Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1726 – F0186.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Patients with Retinal Vein Occlusion (RVO) have differing degrees of response to anti-VEGF treatment. A retrospective comparative study was performed to determine if response to anti-VEGF treatment at 3 months post-initiation of anti-VEGF treatment could predict RVO outcomes, namely Central Subfield Thickness (CST) and Best Visual Acuity (BVA), at the 12-month time point.

Methods : Patients over age 18 with treatment naïve RVO-related macular edema and treated with anti-VEGF injections were included in the study. A machine learning algorithm (Notal Vision Ltd., Tel Aviv, Israel) quantified total retinal fluid (TRF), intraretinal fluid (IRF), and subretinal fluid (SRF). Patients were categorized as early responders (ER) or limited early responders (LER); LER eyes were defined as having CST reduction < 10%, BVA gain < 5 ETDRS letters, or both at 3-months after anti-VEGF initiation. BVA and CST changes over the 12-month period following first anti-VEGF treatment were compared. Statistical analysis involved Levene test, Welch’s t-test, and Welch’s ANOVA.

Results : 116 eyes met inclusion criteria (74 ER, 42 LER). Baseline VA differed between ER (45.8 letters) and LER (62.9 letters) (p < 0.0001). Both 12-month change in BVA and CST varied significantly between early response statuses. Specifically, change in BVA for ER was 21.4 letters and 0.8 letters for LER (p < 0.0001), and the change in CST was -187.1 mm for ER and -104.4 mm for LER (p < 0.05). VA (+19.9 letters, p < 0.0001) and TRF (-613 nl, p < 0.01) significantly improved for ER eyes, but only in the initial 3-month period. Changes in VA and fluid compartments were not significant across all other time points and responder categories.

Conclusions : Functional and anatomical improvements at 12-months were more impressive for ER than LER defined at 3 months. Additionally, this study highlights the potential for 3-month TRF reduction as a marker of early response. Most functional and anatomical gains in ER occurred during the initial 3 months of treatment, with no significant improvements in VA or TRF after the first 3 months. Thus, the 3-month response to anti-VEGF treatments may be a useful biomarker to predict the prognosis of eyes with RVO treated with anti-VEGF.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×